Story
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO
Summary
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.
Zhejiang Jingxin Pharmaceutical Co., Ltd., a drugmaker already listed in Shenzhen, has renewed its application for an initial public offering on the Hong Kong Stock Exchange. The move underscores the company's continued effort to tap into international capital and broaden its investor base.
Filing Details
According to a disclosure on September 18, the company resubmitted its prospectus to the Main Board of the HKEX. The filing confirms that CITIC Securities is acting as the sole sponsor for the proposed listing.
This marks a second attempt by the pharmaceutical firm to achieve a dual listing. Such a move is a common strategy for mainland Chinese companies seeking access to offshore funding and greater global visibility beyond the domestic A-share market.
Business and Pipeline Focus
Jingxin Pharmaceutical's corporate strategy centers on two core therapeutic areas: central nervous system (CNS) disorders and cardiovascular and cerebrovascular diseases. The company's prospectus highlights its current product portfolio and development pipeline.
AdKey assets mentioned in the filing include:
- Didacinine (京诺宁®): The company's sole approved innovative drug as of the latest practicable date.
- JX2201: A Class 1 innovative drug candidate under development for treating elevated lipoprotein(a) levels.
Market Context
Zhejiang Jingxin Pharmaceutical currently trades on the Shenzhen Stock Exchange under the stock code 002020.SZ. A successful listing in Hong Kong would establish a new fundraising platform for the company and complement its existing presence in the mainland Chinese market, potentially attracting a different class of institutional and international investors.
Read next
More on Stocks
Huawei Unveils Advanced Power and Cooling Solutions for AI Data Centers
Huawei has launched a new suite of energy infrastructure and thermal management products for AI data centers, signaling a strategic shift towards integrated power storage and intelligent liquid cooling systems to meet the demands of high-density computing.
Diamond Cooling Solutions Nearing Industrial Scale-Up Amid AI Chip Power Surge, CITIC Says
A report from CITIC Securities forecasts 2026 as a breakout year for diamond-based thermal management, driven by the extreme power consumption of next-generation AI chips that is pushing traditional cooling materials to their physical limits.
Jiugui Liquor Cuts 447 Distributors, Deepens Partnership with Retailer Pang Dong Lai
The Chinese baijiu maker is overhauling its sales network by reducing its distributor count by over 40% and launching a new budget product with its top retail partner, aiming to navigate a soft consumer market.
Jingxin Pharmaceutical Refiles for Hong Kong IPO, Citing New Insomnia Drug
Zhejiang Jingxin Pharmaceutical Co., Ltd., a Shenzhen-listed drugmaker, has submitted a new application for a mainboard listing on the Hong Kong Stock Exchange, highlighting its strategic shift towards innovative drugs for central nervous system disorders.